Drugs / Hepar-P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01680003 | Sep 2012 → Oct 2013 | NAFLD1 | Nova Laboratories Sdn Bhd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepar-P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01680003 ↗ |
| Known as | EPN 797 | “a Standardised Extract of Phyllanthus Niruri (EPN 797) HEPAR-P capsule” NCT01680003 ↗ |
| Route | Oral | “Two capsules (250mg x 2), three times daily, orally” NCT01680003 ↗ |